Advances in Chondroitinase delivery for Spinal Cord Repair
Advances in Chondroitinase delivery for Spinal Cord Repair
Chondroitin sulfate proteoglycans (CSPGs) present a formidable barrier to regrowing axons following spinal cord injury. CSPGs are secreted in response to injury and their glycosaminoglycan (GAG) side chains present steric hindrance preventing the growth of axons through the lesion site. The enzyme chondroitinase has been proven effective at reducing the CSPG GAG chains, however, there are issues with direct administration of the enzyme specifically due to its limited timeframe of activity. In this perspective article, we discuss the evolution of chondroitinase-based therapy in spinal cord injury as well as up-to-date advances on this critical therapeutic. We describe the success and the limitations around use of the bacterial enzyme namely issues around thermostability. We then discuss current efforts to improve delivery of chondroitinase with a push towards gene therapy, namely through the use of lentiviral and adeno-associated viral vectors, including the temporal modulation of its expression and activity. As a chondroitinase therapy for spinal cord injury inches nearer to the clinic, the drive towards an optimised delivery platform is currently underway.
Chondroitinase, CSPGs, gene therapy, spinal cord injury, viral vectors
Wei, Yuting
7a1bc662-98b7-46e9-a08e-1e94294f8639
Andrews, Melissa
ae987a2f-878e-4ae3-a7a3-a7170712096c
Wei, Yuting
7a1bc662-98b7-46e9-a08e-1e94294f8639
Andrews, Melissa
ae987a2f-878e-4ae3-a7a3-a7170712096c
Wei, Yuting and Andrews, Melissa
(2022)
Advances in Chondroitinase delivery for Spinal Cord Repair.
Journal of Integrative Neuroscience.
(In Press)
Abstract
Chondroitin sulfate proteoglycans (CSPGs) present a formidable barrier to regrowing axons following spinal cord injury. CSPGs are secreted in response to injury and their glycosaminoglycan (GAG) side chains present steric hindrance preventing the growth of axons through the lesion site. The enzyme chondroitinase has been proven effective at reducing the CSPG GAG chains, however, there are issues with direct administration of the enzyme specifically due to its limited timeframe of activity. In this perspective article, we discuss the evolution of chondroitinase-based therapy in spinal cord injury as well as up-to-date advances on this critical therapeutic. We describe the success and the limitations around use of the bacterial enzyme namely issues around thermostability. We then discuss current efforts to improve delivery of chondroitinase with a push towards gene therapy, namely through the use of lentiviral and adeno-associated viral vectors, including the temporal modulation of its expression and activity. As a chondroitinase therapy for spinal cord injury inches nearer to the clinic, the drive towards an optimised delivery platform is currently underway.
Text
JIN21122902-final version updated April
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 15 February 2022
Keywords:
Chondroitinase, CSPGs, gene therapy, spinal cord injury, viral vectors
Identifiers
Local EPrints ID: 456689
URI: http://eprints.soton.ac.uk/id/eprint/456689
PURE UUID: 093048a8-e55a-4789-b2b5-98d56df8f084
Catalogue record
Date deposited: 09 May 2022 16:36
Last modified: 17 Mar 2024 03:44
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
